Printer Friendly

Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.

Tokyo, Japan, Oct 5, 2005 - (JCNN) - Hosokawa Micron and AnGes MG jointly announced on October 3 that Hosokawa Micron has succeeded in encapsulating NF-kappa B decoy oligodeoxynucleotide (NFkB decoy oligo) in a composite nanoparticle.

NFkB decoy oligo is a nucleic acid agent developed by AnGes MG. Using Hosokawa's proprietary PLGA (lactide-co-gycolide) nanoparticles, it can improve the efficiency of drug delivery.

In addition, Hosokawa Micron has begun assessing the pharmacological effect of NFkB decoy oligo-containing nanoparticle on skin diseases including atopic dermatitis and psoriasis.

The two companies expect that this achievement will contribute to further development in protein, genetic and nucleic acid drugs.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 6, 2005
Previous Article:FANCL Announces Research Results of Antiaging Material Silybin at IFSCC International Conference 2005.
Next Article:PhramaDesign, Pharma Valley Center to Collaborate in Developing Transcriptional Regulator-targeted Anti-tumor Agents.

Related Articles
Transcription factor activation following exposure of an intact lung preparation to metallic particulate matter. (Articles).
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Patents HVJ Envelope Vector in US.
AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |